<DOC>
	<DOCNO>NCT02141230</DOCNO>
	<brief_summary>Following result first survey form part EU RMP Alli® ( RMP survey 1 ; WEUSRTP3350 ) , several amendment information include pack carton Alli® ( orlistat 60 mg ) recommend . The main finding RMP survey 1 large proportion Alli® user body mass index ( BMI ) less ( &lt; ) 28 kg/m2 . ( Note : European indication Alli® adults 18 year old BMI &lt; 28 kg/m2 . ) The proportion respondents overall report possible contraindication Alli® use relatively low . The following change pack label agree implement : : ( 1 ) statement , highlight product BMI 28 add front pack ; ( 2 ) word BMI statement back pack strengthen ; ( 3 ) contraindication highlight bold text ; ( 4 ) statement Alli® use 18 year age modify clarity . In addition , pharmacy reminder card make available retail pharmacist improve awareness prescribe information Alli® . The survey ass whether compliance authorize indication contraindication among purchaser Alli® improve one year marketing revise pack labeling .</brief_summary>
	<brief_title>Risk Management Plan ( RMP ) Survey Purchasers Alli® ( 60 mg Orlistat ) European Union .</brief_title>
	<detailed_description />
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<criteria>Any individual purchase Alli pharmacy personal use provide consent . No exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>